February 2025 FDA New Drug Approvals: Onapgo (apomorphine hydrochloride) is a continuous subcutaneous infusion formulation of the approved dopaminergic agonist apomorphine for the treatment of motor fluctuations (OFF episodes) in adults with advanced Parkinson’s disease. Join our vibrant community on LinkedIn for the latest updates on publishing, research, and pharmaceutical webinars. Don't miss out on exclusive insights and opportunities to elevate your career. Follow us now and be part of the SPSR journey! https://www.linkedin.com/company/spsr2010